Abstract: The present invention relates to a method for detecting the amount of a target polynucleotide in a sample. A combination is provided in a medium. The combination comprises (i) a sample suspected of containing the target polynucleotide, the target polynucleotide being in single stranded form, (ii) a reference polynucleotide comprising a sequence that is common with a sequence of the target polynucleotide, and (iii) a predetermined amount of an oligonucleotide probe that has a sequence that hybridizes with the sequence that is common. The combination is subjected to conditions for amplifying the target polynucleotide and the reference polynucleotide. The conditions permit formation of substantially non-dissociative complexes of the target polynucleotide and the reference polynucleotide, respectively, with the oligonucleotide probe. Furthermore, the predetermined amount of the oligonucleotide probe is less than the expected amount of the amplified target polynucleotide.

Abstract: A computer and its corresponding cache system includes a cache memory, a buffer unit, and a bus transaction queue. The buffer unit includes a plurality of entries suitable for temporarily storing data, address, and attribute information of operations generated by the CPU. A first operation initiated by the load store unit buffers an operation in a first entry of the buffer unit, which initiates a first transaction to be queued in a first entry of the bus transaction queue where the first transaction in the bus transaction queue points to the first entry in the buffer unit. Preferably, the buffer unit is configured to modify the first transaction from a first transaction type to a second transaction type prior to execution in response to an event that alters the data requirements of the queued transaction. Additional utility is achieved by merging multiple store operation that miss to a common cache line into a single entry.

Abstract: Compositions for topical ophthalmic application comprising an aqueous mixture of a non-steroidal anti-inflammatory agent. The compositions are formulated with a pH and concentration of agent chosen to maintain at least some of the therapeutic agent of the formulation in suspension.

Abstract: A cache memory system including a cache memory suitable for coupling to a load/store unit of a CPU, a buffer unit comprised of a plurality of entries each including a data buffer and a corresponding address tag. The system is configured to initiate a data fetch transaction in response to a first store operation that misses in both the cache memory and the buffer unit, to allocate a first entry in the buffer unit, and to write the first store operation's data in the first entry's data buffer. The system is adapted to write data from at least one subsequent store operation into the first entry's data buffer if the subsequent store operation misses in the cache but hits in the first entry of the buffer unit prior to completion of the data fetch transaction. In this manner, the first entry's data buffer includes a composite of the first and subsequent store operations' data.

Abstract: A cache memory system including a cache memory configured for coupling to a load/store unit of a CPU, a buffer unit coupled to said cache memory, and an operation queue comprising a plurality of entries, wherein each valid operation queue entry points to an entry in the buffer unit. The buffer unit includes a plurality of data buffers and each of the data buffers is associated with a corresponding address tag. The system is configured to initiate a data fetch transaction and allocate an entry in the buffer unit in response to a CPU load operation that misses in both the cache memory and the buffer unit. The cache system is further configured to allocate entries in the operation queue in response to subsequent CPU load operations that miss in the cache memory but hit in the buffer unit prior to completion of the data fetch.

Abstract: A data processing system (10) provides a mechanism for choosing when the data stream touch (DST) controller (300) is allowed access to the data cache and MMU (50). The mechanism uses a count value to determine at what point in program execution the DST controller (300) is allowed to interrupt normal load and store accesses. This allows DST prefetches to be optimized for maximum performance of the data processing system (10).

Abstract: Compositions and methods for the modulation of melanin production are provided in which the active component is an adenosine receptor antagonist or agonist.

Abstract: Ophthalmic methods and compositions are disclosed where particles of the dispersed phase of emulsions are themselves dispersed and stably maintained in physical separation by lightly crosslinked, water swellable polymers present in an aqueous polymeric system formulated for administration to the eye in drop or ribbon form. Medicament is dissolved in that dispersed phase is delivered over a sustained release period.

Abstract: Topical ophthalmic compositions for treatment of the eye are provided which comprise aqueous mixtures of a non-steroidal agent having a pKa, a pH, and a concentration of agent chosen so as to maintain at least a therapeutic amount of the agent in suspension and a therapeutic amount of the agent in solution. A method for treating diseases of the eye, including inflammation, is also provided by topically applying such aqueous mixtures to eyes in need of treatment, whereby the therapeutic amount of the drug in solution has an immediate therapeutic effect at full concentration, and the therapeutic amount of drug in suspension has a delayed therapeutic effect by release from the suspension over a period of time by reason of dissolution kinetics.

Abstract: Ophthalmic methods and compositions are disclosed where particles of the dispersed phase of emulsions are themselves dispersed and stably maintained in physical separation by lightly crosslinked, water swellable polymers present in an aqueous polymeric system formulated for administration to the eye in drop or ribbon form. Medicament is dissolved in that dispersed phase is delivered over a sustained release period.

Abstract: Topical ophthalmic medicament delivery system combining an aqueous ophthalmic gel suspension at a pH equal to or greater than 7.5 and an osmotic pressure of from 10 to about 400 mOsM containing a pharmaceutically effective mount of one or more ophthalmic medicaments of from about 0.05% to about 10% by weight, based on the total weight of the suspension, of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less then about 5% by weight of a cross-linking agent. The systems have a viscosity of from about 1,000 to about 30,000 centiposes prior to administration to the eye and remain a gel in the eye for a prolonged period of time allowing for the sustained release of one or medicaments such as amine containing antibiotics alone or in combination with cortiscosteroids.

Abstract: Flavored food and pharmaceutical compositions include one or more flavor additives incorporated within polymeric particles, usually within an internal pore network defined by individual polymeric particles. The polymeric particles are, in turn, dispersed within and/or over a surface of an orally-deliverable matrix material, which is usually a solid or semi-solid substrate. In the case of chewable compositions, the flavor additives will be released into the orally-deliverable matrix material as the composition is chewed and held in the mouth, thus prolonging the flavor of the composition. In the case of dried powders and mixes, the flavor will typically be made available as the product is consumed or be released into the matrix material as the composition is further processed. When two flavors are combined with the polymeric particles, the relative amounts of the additives can be selected to provide simultaneous release and exhaustion of the additives.

Abstract: Topical ophthalmic medicament delivery system combining an aqueous ophthalmic gel suspension at a pH equal to or greater than 7.5 and an osmotic pressure of from 10 to about 400 mOsM containing a pharmaceutically effective amount of one or more ophthalmic medicaments of from about 0.05% to about 10% by weight, based on the total weight of the suspension, of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less then about 5% by weight of a cross-linking agent. The systems have a viscosity of from about 1,000 to about 30,000 centiposes prior to administration to the eye and remain a gel in the eye for a prolonged period of time allowing for the sustained release of one or medicaments such as amine containing antibiotics alone or in combination with cortiscosteroids.

Abstract: A composition for the controlled release of an active substance comprises a polymeric particle matrix, where each particle defines a network of internal pores. The active substance is entrapped within the pore network together with a blocking agent having physical and chemical characteristics selected to modify the release rate of the active substance from the internal pore network. In an exemplary embodiment, drugs may be selectively delivered to the intestines using an enteric material as the blocking agent. The enteric material remains intact in the stomach but will degrade under the pH conditions of the intestines. In another exemplary embodiment, the sustained release formulation employs a blocking agent which remains stable under the expected conditions of the environment to which the active substance is to be released.